肺活量计市场- 按产品（设备、软体、消耗品和配件）、技术（峰值流量计、容量和流量测量）、应用（气喘、慢性阻塞性肺病、囊性和肺纤维化）、最终用途（医院、居家照护） - 全球预测, 2024 - 2032

由于慢性阻塞性肺病 (COPD)、气喘和囊性纤维化等呼吸系统疾病盛行率的不断上升，肺活量计市场规模从 2024 年到 2032 年的复合年增长率可能超过 9.6%。根据世界卫生组织的数据，慢性阻塞性肺病每年夺走超过 300 万人的生命。随着全球对呼吸系统疾病早期检测和管理重要性的认识不断提高，医疗保健提供者越来越多地采用肺活量计作为重要的诊断工具。此外，全球人口老化正在促进市场成长，因为老年人更容易患呼吸系统疾病，需要定期监测肺功能。

此外，对预防性医疗保健和健康计划的日益重视正在促进肺活量测定法测试作为各种医疗保健环境中的常规筛检工具的采用。将肺活量测定法整合到远距医疗平台和电子健康记录中，有助于远端监控和资料管理，从而提高患者护理和治疗效果。旨在改善呼吸保健基础设施和促进早期疾病检测的政府措施和医疗保健政策也将有助于推动市场成长。

肺活量计产业根据产品、技术、应用、最终用途和地区进行分类。

从应用来看，到2032年，肺纤维化领域的市场规模将达到9.7%的成长率。肺量计是评估肺纤维化患者的肺功能和监测疾病进展的重要诊断工具。随着人们越来越认识到定期肺功能检测在疾病管理中的重要性，专门从事呼吸护理的医疗保健提供者对肺活量计的需求将继续上升。

就最终用途而言，家庭护理设置领域的肺活量计市场预计将在2024 年和2032 年期间以10% 的复合年增长率产生可观的收入。的日益重视。便携式和用户友好的肺活量计提供的便利性和可及性使患者能够方便地进行肺功能测试，而无需经常访问医疗机构。

到 2032 年，亚太地区肺活量计行业规模将以 11.4% 的复合年增长率增长。许多亚洲国家的人口老化，加上生活方式和饮食习惯的改变，导致慢性阻塞性肺病和气喘的盛行率升高。此外，旨在改善医疗基础设施和提高呼吸健康意识的政府措施将刺激区域产业的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 呼吸道疾病盛行率上升
    • 设备技术进步
    • 人们越来越偏好家庭医疗保健
  • 产业陷阱与挑战
    • 缺乏熟练的专业人员和报销政策
• 成长潜力分析
• 监管环境
• 技术景观
• 报销场景
• 波特的分析
• PESTEL分析
• 未来市场趋势

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

• 主要趋势
• 装置
  • 手持式
  • 桌上
  • 桌面
• 软体
• 耗材及配件

第 6 章：市场估计与预测：按技术划分，2018 年 - 2032 年

• 主要趋势
• 体积测量
• 流量测量
• 峰值流量计

第 7 章：市场估计与预测：按应用分类，2018 年 - 2032 年

• 主要趋势
• 气喘
• 慢性阻塞性肺病
• 囊肿纤维化
• 肺纤维化
• 其他应用

第 8 章：市场估计与预测：按最终用途，2018 - 2032 年

• 主要趋势
• 医院和诊所
• 家庭护理设置
• 临床实验室
• 其他最终用户

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• COSMED srl
• FUKUDA SANGYO CO., LTD.
• Geratherm Medical AG
• Hill-Rom Holdings, Inc. (Baxter International)
• Koninklijke Philips N.V.
• ndd Medical Technologies
• Schiller AG
• Sibelmed
• Teleflex Incorporated
• Vitalograph
• Vyaire Medical Inc.

Spirometer Market size is likely to record more than 9.6% CAGR from 2024 and 2032 propelled by the increasing prevalence of respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. As per WHO, COPD claims the lives of over 3 million individuals annually. With rising global awareness about the importance of early detection and management of respiratory conditions, healthcare providers are increasingly adopting spirometers as essential diagnostic tools. Moreover, the aging population worldwide is contributing to the market growth, as elderly individuals are more prone to respiratory ailments and require regular monitoring of the lung functions.

Furthermore, the growing emphasis on preventive healthcare and wellness initiatives is fostering the adoption of spirometry testing as a routine screening tool in various healthcare settings. The integration of spirometry into telemedicine platforms and electronic health records facilitates remote monitoring and data management for enhancing patient care and treatment outcomes. Government initiatives and healthcare policies aimed at improving respiratory healthcare infrastructure and promoting early disease detection will also help in driving the market growth.

The spirometer industry is classified based on product, technology, application, end-use and region.

By application, the market size from the pulmonary fibrosis segment will record a 9.7% growth rate through 2032. Early detection and monitoring of pulmonary function are crucial for managing the rising prevalence of pulmonary fibrosis effectively. Spirometry serves as a vital diagnostic tool for assessing lung functions and monitoring disease progression in pulmonary fibrosis patients. With growing awareness about the importance of regular pulmonary function testing in disease management, the demand for spirometers among healthcare providers specializing in respiratory care will continue to rise.

In terms of end-use, the spirometer market from the homecare settings segment is poised to generate substantial revenue at 10% CAGR during 2024 and 2032. The growth is favored by the increasing emphasis on remote patient monitoring and management of chronic respiratory conditions in the comfort of the homes of patients. The convenience and accessibility offered by portable and user-friendly spirometers enables patients to perform lung function tests conveniently without the need for frequent visits to healthcare facilities.

Asia Pacific spirometers industry size will grow at 11.4% CAGR through 2032. The rapid urbanization and industrialization is leading to increasing levels of air pollution and the subsequent rise in respiratory diseases. The aging population in many Asian countries, coupled with changing lifestyles and dietary habits is contributing to a higher prevalence COPD and asthma. Additionally, government initiatives aimed at improving healthcare infrastructure and raising awareness about respiratory health will stimulate the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of respiratory diseases
    • 3.2.1.2 Technological advancements in devices
    • 3.2.1.3 Growing preference for home healthcare
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of skilled professionals and reimbursement policies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Reimbursement scenario
• 3.7 Porter's analysis
  • 3.7.1 Supplier power
  • 3.7.2 Buyer power
  • 3.7.3 Threat of new entrants
  • 3.7.4 Threat of substitutes
  • 3.7.5 Industry rivalry
• 3.8 PESTEL analysis
• 3.9 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Devices
  • 5.2.1 Hand held
  • 5.2.2 Table top
  • 5.2.3 Desktop
• 5.3 Software
• 5.4 Consumables & accessories

Chapter 6 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Volume measurement
• 6.3 Flow measurement
• 6.4 Peak flow meters

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Asthma
• 7.3 COPD
• 7.4 Cystic fibrosis
• 7.5 Pulmonary fibrosis
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Homecare settings
• 8.4 Clinical laboratories
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 COSMED srl
• 10.2 FUKUDA SANGYO CO., LTD.
• 10.3 Geratherm Medical AG
• 10.4 Hill-Rom Holdings, Inc. (Baxter International)
• 10.5 Koninklijke Philips N.V.
• 10.6 ndd Medical Technologies
• 10.7 Schiller AG
• 10.8 Sibelmed
• 10.9 Teleflex Incorporated
• 10.10 Vitalograph
• 10.11 Vyaire Medical Inc.